Burkitt Lymphoma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Burkitt Lymphoma – Drugs In Development, 2024 report and make more profitable business decisions.
Burkitt lymphoma is an aggressive and fast-growing type of non-Hodgkin lymphoma (NHL) that primarily affects B cells, a type of white blood cell involved in the immune system. It is named after Denis Burkitt, a surgeon who described the disease in African children in the 1950s. There are three main types of Burkitt lymphoma. Endemic Burkitt lymphoma is most commonly found in equatorial Africa, where it’s associated with the Epstein-Barr virus (EBV) infection and frequently affects children. It often presents as tumors in the jaw or facial bones. Sporadic Burkitt lymphoma is found worldwide, and is less associated with EBV but still affects children and adults. It can involve the abdomen, lymph nodes, bone marrow, or other organs. Immunodeficiency-associated Burkitt lymphoma occurs more commonly in individuals with weakened immune systems, such as those with HIV/AIDS or following organ transplantation. Burkitt lymphomas are characterized by rapid growth, often leading to the development of large tumors within a short period. Common symptoms include swelling of the lymph nodes, fever, night sweats, weight loss, and abdominal pain or swelling if organs in the abdomen are affected.
The Burkitt Lymphoma drugs in development market research report provide comprehensive information on the therapeutics under development for Burkitt Lymphoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Burkitt Lymphoma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Burkitt Lymphoma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 70 molecules, with 56 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Burkitt Lymphoma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Burkitt Lymphoma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Burkitt Lymphoma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Achelois BioPharma IncAugust Pi i Sunyer Biomedical Research Institute
Aurigene Oncology Ltd
Autolus Therapeutics Plc
AVM Biotechnology LLC
Beijing zhikangbo Medical Oncology Research Co Ltd
BioCurate Pty Ltd
BioPact Ventures LLC
Biosyngen Pte Ltd
Bristol-Myers Squibb Co
Ceptur Therapeutics Inc
Cornerstone Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
F. Hoffmann-La Roche Ltd
Genentech USA Inc
Genmab AS
Gilead Sciences Inc
GSK plc
GT Biopharma Inc
Hebei Senlang Biotechnology Co Ltd
Huazhong University of Science & Technology
Iksuda Therapeutics Ltd
Immunitas Therapeutics Inc
JN Biosciences LLC
Karyopharm Therapeutics Inc
Kintor Pharmaceutical Ltd
Meabco AS
Medical College of Wisconsin
Merck & Co Inc
Millennium Pharmaceuticals Inc
Miltenyi Biomedicine GmbH
Mustang Bio Inc
Nanchang University Affiliated Hospital One
National Cancer Institute US
National Center for Cardiovascular Research Carlos III
Nektar Therapeutics
Novartis AG
Orano Med LLC
Oxcia AB
Pacylex Pharmaceuticals Inc
PeproMene Bio Inc
Regeneron Pharmaceuticals Inc
Sian Wuhan Medical Technology Co Ltd
Sichuan University
Sorrento Therapeutics Inc
Stanford University
Sutro Biopharma Inc
Swedish Orphan Biovitrum AB
Takeda Pharmaceutical Co Ltd
Third Military Medical University
UNC Lineberger Comprehensive Cancer Center
University of Colorado Denver
University of Texas MD Anderson Cancer Center
UTC Therapeutics Inc
UWELL Biopharma Inc
Vincerx Pharma Inc
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xuzhou Medical University
Y-mAbs Therapeutics Inc
Yikesite (Beijing) Pharmaceutical Technology Development Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Burkitt Lymphoma reports